{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:55:53Z","timestamp":1790985353683,"version":"4.1.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Agr\u0131 Ibrahim Cecen University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10787-026-02241-2","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:29:52Z","timestamp":1776468592000},"page":"4219-4237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dapagliflozin ameliorates motor deficits in a Parkinson\u2019s disease model induced by 6-OHDA: An integrative in vivo and in silico approach from \u03b1-synuclein\/A2AAR\/TH\/TNF-\u03b1 to APAF-1\/caspase-3 modulation"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6575-6149","authenticated-orcid":false,"given":"Selma","family":"Sezen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza","family":"Burul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2871-0712","authenticated-orcid":false,"given":"Ufuk","family":"Okkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-0409","authenticated-orcid":false,"given":"Mehmet","family":"Karaday\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9765-4569","authenticated-orcid":false,"given":"Mustafa","family":"Ozkaraca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8940-8560","authenticated-orcid":false,"given":"Cemil","family":"Bayram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3770-2116","authenticated-orcid":false,"given":"Yusuf","family":"G\u00fcl\u015fahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-9547","authenticated-orcid":false,"given":"Irmak","family":"Ferah Okkay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5957-8259","authenticated-orcid":false,"given":"Medine","family":"Gulluce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"10","key":"2241_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/ph16101370","volume":"16","author":"MA Abd Elmaaboud","year":"2023","unstructured":"Abd Elmaaboud MA, Estfanous RS, Atef A, Kabel AM, Alnemari KA, Naguib TM, Alsufyani SE, Darwish HW, Arab HH (2023) Dapagliflozin\/hesperidin combination mitigates lipopolysaccharide-induced Alzheimer\u2019s disease in rats. Pharmaceuticals (Basel) 16(10):1370. https:\/\/doi.org\/10.3390\/ph16101370","journal-title":"Pharmaceuticals (Basel)"},{"key":"2241_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s11064-025-04538-0","volume":"50","author":"GF Abdelhafez","year":"2025","unstructured":"Abdelhafez GF, Boshra SA, Abo-Zalam HB, Radwan SM (2025) Dapagliflozin ameliorates doxorubicin-induced chemobrain and cognitive abnormalities in rats: modulation of AKT\/GSK-3\u03b2 and Wnt\/\u03b2-catenin pathways. Neurochem Res 50:286. https:\/\/doi.org\/10.1007\/s11064-025-04538-0","journal-title":"Neurochem Res"},{"issue":"2","key":"2241_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.61845\/agrimedical.1471854","volume":"2","author":"\u00d6 Altunlu","year":"2024","unstructured":"Altunlu \u00d6, Topatan E, Al-yaqoobi Z, Burul F, Bayram C, Sezen S, Okkay IF, Okkay U, Hac\u0131m\u00fcft\u00fco\u011flu A (2024) Experimental models in Parkinson\u2019s disease: advantages and disadvantages. A\u011fr\u0131 Med J 2(2):80\u201387. https:\/\/doi.org\/10.61845\/agrimedical.1471854","journal-title":"A\u011fr\u0131 Med J"},{"issue":"12","key":"2241_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1055\/a-1460-8795","volume":"193","author":"S Aludin","year":"2021","unstructured":"Aludin S, Schmill LA (2021) MRI signs of Parkinson\u2019s disease and atypical parkinsonism. Magnetresonanztomografische Zeichen des idiopathischen Parkinson-Syndroms sowie atypischer Parkinson-Syndrome. RoFo 193(12):1403\u20131410. https:\/\/doi.org\/10.1055\/a-1460-8795","journal-title":"RoFo"},{"issue":"4","key":"2241_CR5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","volume":"12","author":"HH Arab","year":"2021","unstructured":"Arab HH, Safar MM, Shahin NN (2021) Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model. ACS Chem Neurosci 12(4):689\u2013703. https:\/\/doi.org\/10.1021\/acschemneuro.0c00722","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"2241_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.5336\/biostatic.2018-62787","volume":"10","author":"AK Arslan","year":"2018","unstructured":"Arslan AK, Yasar S, Colak C, Yologlu S (2018) WSSPAS: An interactive web application for sample size and power analysis with R using shiny. Turkiye Klinikleri J Biostatistics 10(3):224\u2013246. https:\/\/doi.org\/10.5336\/biostatic.2018-62787","journal-title":"Turkiye Klinikleri J Biostatistics"},{"issue":"19","key":"2241_CR7","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.3390\/molecules25194382","volume":"25","author":"S Aryal","year":"2020","unstructured":"Aryal S, Skinner T, Bridges B, Weber JT (2020) The pathology of Parkinson\u2019s disease and potential benefit of dietary polyphenols. Molecules 25(19):4382. https:\/\/doi.org\/10.3390\/molecules25194382","journal-title":"Molecules"},{"key":"2241_CR8","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s11011-022-01021-5","volume":"37","author":"A Asemi-Rad","year":"2022","unstructured":"Asemi-Rad A, Moafi M, Aliaghaei A, Abbaszadeh HA, Abdollahifar MA, Ebrahimi MJ, Heidari MH, Sadeghi Y (2022) The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson\u2019s disease. Metab Brain Dis 37:2677\u20132685. https:\/\/doi.org\/10.1007\/s11011-022-01021-5","journal-title":"Metab Brain Dis"},{"issue":"1","key":"2241_CR9","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jsfa.70140","volume":"106","author":"B Ayd\u0131n","year":"2026","unstructured":"Ayd\u0131n B, Ertu\u011frul MS, Ayd\u0131n \u0130\u00c7, U\u011fan RA, \u00d6zkaraca M, Yuca H, \u00d6zbek H, Kazaz C, Okkay U, Karakaya S, Hac\u0131m\u00fcft\u00fco\u011flu A, G\u00fcvenalp Z Bioactive properties of Vicia canescens subsp. variegata (Willd.), Davis PH (2026) Fabaceae: antioxidant, antiparkinsonian and relevance to food and agriculture use. J Sci Food Agric 106(1):172\u2013184. https:\/\/doi.org\/10.1002\/jsfa.70140","journal-title":"J Sci Food Agric"},{"issue":"1","key":"2241_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV (2020) Parkinson disease. Eur J Neurol 27(1):27\u201342. https:\/\/doi.org\/10.1111\/ene.14108","journal-title":"Eur J Neurol"},{"issue":"1","key":"2241_CR11","doi-asserted-by":"publisher","first-page":"e1336","DOI":"10.1002\/vms3.1336","volume":"10","author":"M Bayraktar","year":"2024","unstructured":"Bayraktar M, Hac\u0131m\u00fcft\u00fco\u011flu A, Okkay U, Ko\u00e7ak MN, K\u00f6seda\u011f M, Tekin E, \u00c7elik M, Okkay IF, Bayram C, Ertu\u011frul MS, Sezen S (2024) Use of bee venom in preventive medicine: an experimental hepatic encephalopathy study in rats. Vet Med Sci 10(1):e1336. https:\/\/doi.org\/10.1002\/vms3.1336","journal-title":"Vet Med Sci"},{"issue":"3","key":"2241_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V (2023) Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis 14(3):176. https:\/\/doi.org\/10.1038\/s41419-023-05672-9","journal-title":"Cell Death Dis"},{"issue":"8","key":"2241_CR13","doi-asserted-by":"publisher","first-page":"7095","DOI":"10.3390\/ijms24087095","volume":"24","author":"KH Chang","year":"2023","unstructured":"Chang KH, Liu CH, Wang YR, Lo YS, Chang CW, Wu HC, Chen CM (2023) Upregulation of APAF1 and CSF1R in peripheral blood mononuclear cells of Parkinson\u2019s disease. Int J Mol Sci 24(8):7095. https:\/\/doi.org\/10.3390\/ijms24087095","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2241_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.expneurol.2010.11.010","volume":"227","author":"M Chertoff","year":"2011","unstructured":"Chertoff M, Di Paolo N, Schoeneberg A, Depino A, Ferrari C, Wurst W, Pfizenmaier K, Eisel U, Pitossi F (2011) Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor \u03b1 in the nigrostriatal dopaminergic circuit of adult mice. Exp Neurol 227(2):237\u2013251. https:\/\/doi.org\/10.1016\/j.expneurol.2010.11.010","journal-title":"Exp Neurol"},{"issue":"14","key":"2241_CR15","doi-asserted-by":"publisher","first-page":"7952","DOI":"10.3390\/ijms25147952","volume":"25","author":"EH Choi","year":"2024","unstructured":"Choi EH, Kim MH, Park SJ (2024) Targeting mitochondrial dysfunction and reactive oxygen species for neurodegenerative disease treatment. Int J Mol Sci 25(14):7952. https:\/\/doi.org\/10.3390\/ijms25147952","journal-title":"Int J Mol Sci"},{"key":"2241_CR16","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1007\/s12035-013-8598-0","volume":"49","author":"T Chotibut","year":"2014","unstructured":"Chotibut T, Davis RW, Arnold JC, Frenchek Z, Gurwara S, Bondada V, Geddes JW, Salvatore MF (2014) Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson\u2019s model. Mol Neurobiol 49:1282\u20131292. https:\/\/doi.org\/10.1007\/s12035-013-8598-0","journal-title":"Mol Neurobiol"},{"key":"2241_CR17","unstructured":"ClinicalTrials.gov (2024) Anti-diabetic medications to fight PD and LBD (NCT06263673). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06263673. Accessed 2 May 2024"},{"issue":"4","key":"2241_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/mdc3.12082","volume":"1","author":"J DiFrancisco-Donoghue","year":"2014","unstructured":"DiFrancisco-Donoghue J, Rabin E, Lamberg EM, Werner WG (2014) Effects of tyrosine on Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Mov Disord Clin Pract 1(4):348\u2013353. https:\/\/doi.org\/10.1002\/mdc3.12082","journal-title":"Mov Disord Clin Pract"},{"issue":"s1","key":"2241_CR19","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8(s1):S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2241_CR20","doi-asserted-by":"publisher","first-page":"43706","DOI":"10.1038\/s41598-025-27555-z","volume":"15","author":"VA Dos Santos","year":"2025","unstructured":"Dos Santos VA, Viotto ACR, Nascimento MM, Bernardo DRD, Shimizu MHM, de Sena CR, Seguro AC, Volpini RA, de Bragan\u00e7a AC, Canale D (2025) Dapagliflozin treatment ameliorates oxidative stress, apoptosis and inflammation in tenofovir-induced nephrotoxicity in rats. Sci Rep 15(1):43706. https:\/\/doi.org\/10.1038\/s41598-025-27555-z","journal-title":"Sci Rep"},{"key":"2241_CR21","doi-asserted-by":"publisher","first-page":"118076","DOI":"10.1016\/j.lfs.2020.118076","volume":"257","author":"AE El-Sahar","year":"2020","unstructured":"El-Sahar AE, Rastanawi AA, El-Yamany MF, Saad MA (2020) Dapagliflozin improves behavioral dysfunction of Huntington\u2019s disease in rats via inhibiting apoptosis-related glycolysis. Life Sci 257:118076. https:\/\/doi.org\/10.1016\/j.lfs.2020.118076","journal-title":"Life Sci"},{"key":"2241_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neuroscience.2024.07.013","volume":"554","author":"MA Erdogan","year":"2024","unstructured":"Erdogan MA, Nesil P, Altuntas I, Sirin C, Uyanikgil Y, Erbas O (2024) Amelioration of propionic acid-induced autism spectrum disorder in rats through dapagliflozin: the role of IGF-1\/IGFBP-3 and the Nrf2 antioxidant pathway. Neuroscience 554:16\u201325. https:\/\/doi.org\/10.1016\/j.neuroscience.2024.07.013","journal-title":"Neuroscience"},{"key":"2241_CR23","doi-asserted-by":"publisher","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch4","volume-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects","author":"NS Erekat","year":"2018","unstructured":"Erekat NS (2018) Apoptosis and its role in Parkinson\u2019s disease. In: Stoker TB, Greenland JC (eds) Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects. Codon, Brisbane. https:\/\/doi.org\/10.15586\/codonpublications.parkinsonsdisease.2018.ch4(AU)"},{"key":"2241_CR24","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fnins.2019.00683","volume":"13","author":"A Falconi","year":"2019","unstructured":"Falconi A, Bonito-Oliva A, Di Bartolomeo M, Massimini M, Fattapposta F, Locuratolo N, Dainese E, Pascale E, Fisone G, D\u2019Addario C (2019) On the role of adenosine A2A receptor gene transcriptional regulation in Parkinson\u2019s disease. Front Neurosci 13:683. https:\/\/doi.org\/10.3389\/fnins.2019.00683","journal-title":"Front Neurosci"},{"issue":"11","key":"2241_CR25","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00221-021-06186-6","volume":"239","author":"Y Feng","year":"2021","unstructured":"Feng Y, Zhou S, Sun J (2021) Exercise increases striatal Glu reuptake and improves motor dysfunction in 6-OHDA-induced Parkinson\u2019s disease rats. Exp Brain Res 239(11):3277\u20133287. https:\/\/doi.org\/10.1007\/s00221-021-06186-6","journal-title":"Exp Brain Res"},{"issue":"17","key":"2241_CR26","doi-asserted-by":"publisher","first-page":"e70309","DOI":"10.14814\/phy2.70309","volume":"13","author":"F Forouzanfar","year":"2025","unstructured":"Forouzanfar F, Hosseini M, Ahmadzadeh AM, Pourbagher-Shahri AM (2025) Neuroprotective effect of cedrol in a male rat model of Parkinson\u2019s disease. Physiol Rep 13(17):e70309. https:\/\/doi.org\/10.14814\/phy2.70309","journal-title":"Physiol Rep"},{"issue":"02","key":"2241_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","volume":"37","author":"ME Freitas","year":"2017","unstructured":"Freitas ME, Hess CW, Fox SH (2017) Motor complications of dopaminergic medications in Parkinson\u2019s disease. Semin Neurol 37(02):147\u2013157. https:\/\/doi.org\/10.1055\/s-0037-1602423","journal-title":"Semin Neurol"},{"issue":"8","key":"2241_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41419-024-07014-9","volume":"15","author":"J Garc\u00eda-Revilla","year":"2024","unstructured":"Garc\u00eda-Revilla J, Ruiz R, Espinosa-Oliva AM, Santiago M, Garc\u00eda-Dom\u00ednguez I, Camprub\u00ed-Ferrer L, Bachiller S, Deierborg T, Joseph B, de Pablos RM, Rodr\u00edguez-G\u00f3mez JA, Venero JL (2024) Dopaminergic neurons lacking caspase-3 avoid apoptosis but undergo necrosis after MPTP treatment inducing a Galectin-3-dependent selective microglial phagocytic response. Cell Death Dis 15(8):625. https:\/\/doi.org\/10.1038\/s41419-024-07014-9","journal-title":"Cell Death Dis"},{"key":"2241_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-40095-4","author":"OL Gundogdu","year":"2026","unstructured":"Gundogdu OL, Burul F, Akyol ET, Okkay U, Yesilyurt F, Yildiz FB, Okkay IF, Ozkaraca M, Hacimuftuoglu A (2026) Targeting AT1 receptors with telmisartan protects SH-SY5Y cells from 6-OHDA induced Parkinsonian neurotoxicity. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-026-40095-4","journal-title":"Sci Rep"},{"issue":"8","key":"2241_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/17512433.2024.2359955","volume":"17","author":"SA Hamed","year":"2024","unstructured":"Hamed SA, Hadad AFE (2024) The effect of anticholinergic drugs on cognition of patients with Parkinson\u2019s disease: a cohort study from the Egyptian population. Expert Rev Clin Pharmacol 17(8):743\u2013753. https:\/\/doi.org\/10.1080\/17512433.2024.2359955","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"2241_CR31","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1073\/pnas.040556597","volume":"97","author":"A Hartmann","year":"2000","unstructured":"Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson\u2019s disease. Proc Natl Acad Sci USA 97(6):2875\u20132880. https:\/\/doi.org\/10.1073\/pnas.040556597","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2241_CR32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1124\/pharmrev.123.001111","volume":"76","author":"K Hassanzadeh","year":"2024","unstructured":"Hassanzadeh K, Liu J, Maddila S, Mouradian MM (2024) Posttranslational modifications of \u03b1-synuclein, their therapeutic potential, and crosstalk in health and neurodegenerative diseases. Pharmacol Rev 76(6):1254\u20131290. https:\/\/doi.org\/10.1124\/pharmrev.123.001111","journal-title":"Pharmacol Rev"},{"issue":"17","key":"2241_CR33","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1111\/febs.14970","volume":"286","author":"E Hollville","year":"2019","unstructured":"Hollville E, Romero SE, Deshmukh M (2019) Apoptotic cell death regulation in neurons. FEBS J 286(17):3276\u20133298. https:\/\/doi.org\/10.1111\/febs.14970","journal-title":"FEBS J"},{"issue":"1","key":"2241_CR34","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/ijms24010351","volume":"24","author":"CY Hsieh","year":"2022","unstructured":"Hsieh CY, Sung SF (2022) From kidney protection to stroke prevention: the potential role of sodium glucose cotransporter-2 inhibitors. Int J Mol Sci 24(1):351. https:\/\/doi.org\/10.3390\/ijms24010351","journal-title":"Int J Mol Sci"},{"issue":"Pt A","key":"2241_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.expneurol.2016.05.040","volume":"283","author":"Q Hu","year":"2016","unstructured":"Hu Q, Ren X, Liu Y, Li Z, Zhang L, Chen X, He C, Chen JF (2016) Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy. Exp Neurol 283(Pt A):213\u2013223. https:\/\/doi.org\/10.1016\/j.expneurol.2016.05.040","journal-title":"Exp Neurol"},{"issue":"12","key":"2241_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1055\/a-1771-6225","volume":"90","author":"WH Jost","year":"2022","unstructured":"Jost WH, T\u00f6nges L (2022) Adenosin A2A rezeptorantagonisten ALS therapieoption beim idiopathischen Parkinson-syndrom? Fortschr Neurol Psychiatr 90(12):565\u2013570. https:\/\/doi.org\/10.1055\/a-1771-6225","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"1","key":"2241_CR37","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.parkreldis.2020.09.026","volume":"80","author":"T Kanda","year":"2020","unstructured":"Kanda T, Jenner P (2020) Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson\u2019s disease? Parkinsonism Relat Disord 80(1):S21\u2013S27. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.09.026","journal-title":"Parkinsonism Relat Disord"},{"key":"2241_CR38","doi-asserted-by":"publisher","first-page":"109793","DOI":"10.1016\/j.intimp.2023.109793","volume":"116","author":"I Khan","year":"2023","unstructured":"Khan I, Preeti K, Kumar R, Kumar Khatri D, Bala Singh S (2023) Piceatannol promotes neuroprotection by inducing mitophagy and mitobiogenesis in the experimental diabetic peripheral neuropathy and hyperglycemia-induced neurotoxicity. Int Immunopharmacol 116:109793. https:\/\/doi.org\/10.1016\/j.intimp.2023.109793","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2241_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/13813455.2022.2108454","volume":"130","author":"I Khan","year":"2024","unstructured":"Khan I, Preeti K, Kumar R, Khatri DK, Singh SB (2024a) Activation of SIRT1 by silibinin improved mitochondrial health and alleviated the oxidative damage in experimental diabetic neuropathy and high glucose-mediated neurotoxicity. Arch Physiol Biochem 130(4):420\u2013436. https:\/\/doi.org\/10.1080\/13813455.2022.2108454","journal-title":"Arch Physiol Biochem"},{"issue":"7","key":"2241_CR40","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/biomedicines12071442","volume":"12","author":"I Khan","year":"2024","unstructured":"Khan I, Kaur S, Rishi AK, Boire B, Aare M, Singh M (2024b) Cannabidiol and beta-caryophyllene combination attenuates diabetic neuropathy by inhibiting NLRP3 inflammasome\/NF\u03baB through the AMPK\/sirT3\/Nrf2 axis. Biomedicines 12(7):1442. https:\/\/doi.org\/10.3390\/biomedicines12071442","journal-title":"Biomedicines"},{"issue":"5","key":"2241_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M (2009) Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85(5):513\u2013519. https:\/\/doi.org\/10.1038\/clpt.2008.250","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"2241_CR42","doi-asserted-by":"publisher","first-page":"e70596","DOI":"10.1002\/brb3.70596","volume":"15","author":"H Li","year":"2025","unstructured":"Li H, He J, Xuan T, Gu S, Niu X, Ren Y, Zhan X, Cheng J (2025) Immune cell proteins and Parkinson\u2019s disease: a mendelian randomization analysis of causal associations. Brain Behav 15(7):e70596. https:\/\/doi.org\/10.1002\/brb3.70596","journal-title":"Brain Behav"},{"key":"2241_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","volume":"13","author":"B Lin","year":"2014","unstructured":"Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S (2014) Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 13:148. https:\/\/doi.org\/10.1186\/s12933-014-0148-1","journal-title":"Cardiovasc Diabetol"},{"key":"2241_CR44","doi-asserted-by":"publisher","first-page":"106169","DOI":"10.1016\/j.nbd.2023.106169","volume":"183","author":"S Luchetti","year":"2023","unstructured":"Luchetti S, Liere P, Pianos A, Verwer RWH, Sluiter A, Huitinga I, Schumacher M, Swaab DF, Mason MRJ (2023) Disease stage-dependent changes in brain levels and neuroprotective effects of neuroactive steroids in Parkinson\u2019s disease. Neurobiol Dis 183:106169. https:\/\/doi.org\/10.1016\/j.nbd.2023.106169","journal-title":"Neurobiol Dis"},{"issue":"16","key":"2241_CR45","doi-asserted-by":"publisher","first-page":"e3337","DOI":"10.21769\/BioProtoc.3337","volume":"9","author":"LAV Magno","year":"2019","unstructured":"Magno LAV, Collodetti M, Tenza-Ferrer H, Romano-Silva MA (2019) Cylinder test to assess sensory-motor function in a mouse model of parkinson\u2019s disease. Bio-protocol 9(16):e3337. https:\/\/doi.org\/10.21769\/BioProtoc.3337","journal-title":"Bio-protocol"},{"issue":"6","key":"2241_CR46","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11064-025-04586-6","volume":"50","author":"E Manca","year":"2025","unstructured":"Manca E, Corsi S, Fanni S, Noli B, Manai AL, Bassu G, Giulia C, Casu MA, Frau R, Pardon M-C, Cappelletti G, Mazzetti S, Carta M, Cocco C (2025) Early dopaminergic dysfunction induces PRO-VGF changes in blood and brain of rats with alpha-synuclein overexpression. Neurochem Res 50(6):344. https:\/\/doi.org\/10.1007\/s11064-025-04586-6","journal-title":"Neurochem Res"},{"issue":"1","key":"2241_CR47","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10787-023-01384-w","volume":"32","author":"NN Mohammed","year":"2024","unstructured":"Mohammed NN, Tadros MG, George MY (2024) Empagliflozin repurposing in Parkinson\u2019s disease; modulation of oxidative stress, neuroinflammation, AMPK\/SIRT-1\/PGC-1\u03b1, and wnt\/\u03b2-catenin pathways. Inflammopharmacology 32(1):777\u2013794. https:\/\/doi.org\/10.1007\/s10787-023-01384-w","journal-title":"Inflammopharmacology"},{"issue":"4","key":"2241_CR48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pathophys.2013.10.001","volume":"20","author":"A Moradganjeh","year":"2013","unstructured":"Moradganjeh A, Ziai SA, Roghani M (2013) Losartan pretreatment reduces neurodegeneration and behavioural symptoms in 6-hydroxydopamine induced unilateral rat model of Parkinson\u2019s disease. Pathophysiology 20(4):243\u2013248. https:\/\/doi.org\/10.1016\/j.pathophys.2013.10.001","journal-title":"Pathophysiology"},{"key":"2241_CR49","doi-asserted-by":"publisher","first-page":"29835","DOI":"10.18632\/oncotarget.8104","volume":"7","author":"SV More","year":"2016","unstructured":"More SV, Choi DK (2016) Emerging preclinical pharmacological targets for Parkinson\u2019s disease. Oncotarget 7:29835\u201329863. https:\/\/doi.org\/10.18632\/oncotarget.8104","journal-title":"Oncotarget"},{"issue":"7","key":"2241_CR50","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/molecules27072366","volume":"27","author":"A Mori","year":"2022","unstructured":"Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P (2022) The pharmacological potential of adenosine A2A receptor antagonists for treating Parkinson\u2019s disease. Molecules 27(7):2366. https:\/\/doi.org\/10.3390\/molecules27072366","journal-title":"Molecules"},{"key":"2241_CR51","doi-asserted-by":"publisher","first-page":"110002","DOI":"10.1016\/j.cbi.2022.110002","volume":"362","author":"TK Motawi","year":"2022","unstructured":"Motawi TK, Al-Kady RH, Abdelraouf SM, Senousy MA (2022) Empagliflozin alleviates endoplasmic reticulum stress and augments autophagy in rotenone-induced Parkinson\u2019s disease in rats: targeting the GRP78\/PERK\/eIF2\u03b1\/CHOP pathway and miR-211-5p. Chem-Biol Interact 362:110002. https:\/\/doi.org\/10.1016\/j.cbi.2022.110002","journal-title":"Chem-Biol Interact"},{"key":"2241_CR52","doi-asserted-by":"publisher","first-page":"100812","DOI":"10.1016\/j.chphi.2024.100812","volume":"10","author":"UM Mugundan","year":"2025","unstructured":"Mugundan UM, Sekar P, Ganesan RM (2025) Repurposing antiviral drugs targeting the PARP-1 and HER2 pathways with multifaceted impacts through integrated network analysis and molecular mechanics. Chem Phys Impact 10:100812. https:\/\/doi.org\/10.1016\/j.chphi.2024.100812","journal-title":"Chem Phys Impact"},{"key":"2241_CR53","doi-asserted-by":"publisher","first-page":"105760","DOI":"10.1016\/j.neuint.2024.105760","volume":"177","author":"S Negi","year":"2024","unstructured":"Negi S, Khurana N, Duggal N (2024) The misfolding mystery: \u03b1-synuclein and the pathogenesis of Parkinson\u2019s disease. Neurochem Int 177:105760. https:\/\/doi.org\/10.1016\/j.neuint.2024.105760","journal-title":"Neurochem Int"},{"issue":"9","key":"2241_CR54","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau VV (2020) Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci 21(9):3165. https:\/\/doi.org\/10.3390\/ijms21093165","journal-title":"Int J Mol Sci"},{"key":"2241_CR56","doi-asserted-by":"publisher","first-page":"110319","DOI":"10.1016\/j.neuropharm.2025.110319","volume":"268","author":"AG O\u2019Mahony","year":"2025","unstructured":"O\u2019Mahony AG, Mazzocchi M, Morris A, Morales-Prieto N, Guinane C, Wyatt SL, Collins LM, Sullivan AM, O\u2019Keeffe GW (2025) The class-IIa HDAC inhibitor TMP269 promotes BMP-Smad signalling and is neuroprotective in vitro and in vivo 6-hydroxydopamine models of Parkinson\u2019s disease. Neuropharmacology 268:110319. https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110319","journal-title":"Neuropharmacology"},{"issue":"5","key":"2241_CR55","doi-asserted-by":"publisher","first-page":"e14028","DOI":"10.1111\/and.14028","volume":"53","author":"U Okkay","year":"2021","unstructured":"Okkay U, Ferah Okkay I, Cicek B, Aydin IC, Ertugrul MS, Bayram C, Senyayla S, Sezen S, Mendil AS, Guven L, Hacimuftuoglu A (2021) Achillea millefolium alleviates testicular damage in paclitaxel-intoxicated rats via attenuation of testicular oxido-inflammatory stress and apoptotic responses. Andrologia 53(5):e14028. https:\/\/doi.org\/10.1111\/and.14028","journal-title":"Andrologia"},{"key":"2241_CR57","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.2147\/NDT.S530827","volume":"21","author":"Q Pan","year":"2025","unstructured":"Pan Q, Lu J, Xiao Z, Zhang H, Liu G, Li Y (2025) Construction of a rat model of hemilateral Parkinson\u2019s disease induced by human wild-type \u03b1-synuclein overexpression. Neuropsychiatr Dis Treat 21:2183\u20132194. https:\/\/doi.org\/10.2147\/NDT.S530827","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2241_CR58","doi-asserted-by":"publisher","first-page":"1419108","DOI":"10.3389\/fnana.2024.1419108","volume":"18","author":"LFAT Pedr\u00e3o","year":"2024","unstructured":"Pedr\u00e3o LFAT, Medeiros POS, Leandro EC, Falquetto B (2024) Parkinson\u2019s disease models and death signaling: what do we know until now? Front Neuroanat 18:1419108. https:\/\/doi.org\/10.3389\/fnana.2024.1419108","journal-title":"Front Neuroanat"},{"issue":"24","key":"2241_CR59","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.3390\/nu16244368","volume":"16","author":"B Pekdemir","year":"2024","unstructured":"Pekdemir B, Raposo A, Saraiva A, Lima MJ, Alsharari ZD, BinMowyna MN, Karav S (2024) Mechanisms and potential benefits of neuroprotective agents in neurological health. Nutrients 16(24):4368. https:\/\/doi.org\/10.3390\/nu16244368","journal-title":"Nutrients"},{"issue":"7","key":"2241_CR60","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1111\/bph.15193","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, W\u00fcrbel H (2020) The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol 18(7):e3000410. https:\/\/doi.org\/10.1111\/bph.15193","journal-title":"PLoS Biol"},{"key":"2241_CR61","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00702-018-1848-6","volume":"125","author":"A Pinna","year":"2018","unstructured":"Pinna A, Serra M, Morelli M, Simola N (2018) Role of adenosine A2A receptors in motor control: relevance to Parkinson\u2019s disease and dyskinesia. J Neural Transm 125:1273\u20131286. https:\/\/doi.org\/10.1007\/s00702-018-1848-6","journal-title":"J Neural Transm"},{"issue":"6","key":"2241_CR62","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s11011-023-01235-1","volume":"38","author":"K Preeti","year":"2023","unstructured":"Preeti K, Fernandes V, Sood A, Khan I, Khatri DK, Singh SB (2023) Correction to: Necrostatin-1 S mitigates type-2 diabetes-associated cognitive decrement and lipotoxicity-induced neuro-microglia changes through p-RIPK-RIPK3-p-MLKL axis. Metab Brain Dis 38(6):2193\u20132196. https:\/\/doi.org\/10.1007\/s11011-023-01235-1","journal-title":"Metab Brain Dis"},{"key":"2241_CR63","doi-asserted-by":"publisher","first-page":"53951","DOI":"10.3791\/53951","volume":"111","author":"M Rattka","year":"2016","unstructured":"Rattka M, Fluri F, Krsti\u0107 M, Asan E, Volkmann J (2016) A novel approach to assess motor outcome of deep brain stimulation effects in the hemiparkinsonian rat: staircase and cylinder test. J Vis Exp 111:53951. https:\/\/doi.org\/10.3791\/53951","journal-title":"J Vis Exp"},{"key":"2241_CR64","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00702-022-02488-3","volume":"129","author":"WD Rausch","year":"2022","unstructured":"Rausch WD, Wang F, Radad K (2022) From the tyrosine hydroxylase hypothesis of Parkinson\u2019s disease to modern strategies: a short historical overview. J Neural Transm 129:487\u2013495. https:\/\/doi.org\/10.1007\/s00702-022-02488-3","journal-title":"J Neural Transm"},{"key":"2241_CR65","doi-asserted-by":"publisher","first-page":"106062","DOI":"10.1016\/j.phrs.2022.106062","volume":"176","author":"MR Rizzo","year":"2022","unstructured":"Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, Capuano A, Paolisso G (2022) Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res 176:106062. https:\/\/doi.org\/10.1016\/j.phrs.2022.106062","journal-title":"Pharmacol Res"},{"issue":"5","key":"2241_CR66","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ph16050753","volume":"16","author":"WA Samman","year":"2023","unstructured":"Samman WA, Selim SM, El Fayoumi HM, El-Sayed NM, Mehanna ET, Hazem RM (2023) Dapagliflozin ameliorates cognitive impairment in aluminum-chloride-induced Alzheimer\u2019s disease via modulation of AMPK\/mTOR, oxidative stress and glucose metabolism. Pharmaceuticals (Basel) 16(5):753. https:\/\/doi.org\/10.3390\/ph16050753","journal-title":"Pharmaceuticals (Basel)"},{"issue":"16","key":"2241_CR67","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.3390\/cells11162599","volume":"11","author":"EI Semenova","year":"2022","unstructured":"Semenova EI, Vlasov IN, Partevian SA, Rosinskaya AV, Rybolovlev IN, Slominsky PA, Shadrina MI, Alieva AK (2022) Transcriptome profiling reveals differential expression of circadian behavior genes in peripheral blood of monozygotic twins discordant for Parkinson\u2019s disease. Cells 11(16):2599. https:\/\/doi.org\/10.3390\/cells11162599","journal-title":"Cells"},{"issue":"3","key":"2241_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.61845\/agrimedical.1811202","volume":"3","author":"S Sezen","year":"2025","unstructured":"Sezen S (2025) Beyond glycemic control: the pleiotropic potential of SGLT-2 inhibitors. A\u011fr\u0131 Med J 3(3):99\u2013101. https:\/\/doi.org\/10.61845\/agrimedical.1811202","journal-title":"A\u011fr\u0131 Med J"},{"issue":"3","key":"2241_CR69","doi-asserted-by":"publisher","first-page":"87","DOI":"10.62425\/rtpharma.1828403","volume":"3","author":"S Sezen","year":"2026","unstructured":"Sezen S, Burul F (2026) A drug repositioning approach: antidiabetic empagliflozin may be a potential drug for the treatment of ALS. Recent Trends Pharmacol 3(3):87\u201397. https:\/\/doi.org\/10.62425\/rtpharma.1828403","journal-title":"Recent Trends Pharmacol"},{"issue":"4","key":"2241_CR73","doi-asserted-by":"publisher","first-page":"341","DOI":"10.47582\/jompac.1198326","volume":"3","author":"S Sezen","year":"2022","unstructured":"Sezen S, Yesilyurt F, \u00d6zkaraca M, Bayram C, Alaylar B, G\u00fcll\u00fcce M, Hac\u0131m\u00fcft\u00fco\u011flu A (2022) Neuroprotective effect of methanol extract of Capparis spinosa L. fruits in an in vitro experimental model of Parkinson\u2019s disease. J Med Palliat Care 3(4):341\u2013346. https:\/\/doi.org\/10.47582\/jompac.1198326","journal-title":"J Med Palliat Care"},{"key":"2241_CR70","doi-asserted-by":"publisher","first-page":"117609","DOI":"10.1007\/s11356-023-30417-8","volume":"30","author":"S Sezen","year":"2023","unstructured":"Sezen S, Ertu\u011frul MS, Balp\u0131nar \u00d6, Bayram C, \u00d6zkaraca M, Okkay IF, Hac\u0131m\u00fcft\u00fco\u011flu A, G\u00fcll\u00fcce M (2023) Assessment of antimicrobial activity and in vitro wound healing potential of ZnO nanoparticles synthesized with Capparis spinosa extract. Environ Sci Pollut Res Int 30:117609\u2013117623. https:\/\/doi.org\/10.1007\/s11356-023-30417-8","journal-title":"Environ Sci Pollut Res Int"},{"key":"2241_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuro.2024.11.005","volume":"106","author":"S Sezen","year":"2025","unstructured":"Sezen S, Karadayi M, Yesilyurt F, Burul F, Gulsahin Y, Ozkaraca M, Okkay U, G\u00fcll\u00fcce M (2025) Acyclovir provides protection against 6-OHDA-induced neurotoxicity in SH-SY5Y cells through the kynurenine pathway. Neurotoxicology 106:1\u20139. https:\/\/doi.org\/10.1016\/j.neuro.2024.11.005","journal-title":"Neurotoxicology"},{"issue":"Pt 1","key":"2241_CR72","doi-asserted-by":"publisher","first-page":"107635","DOI":"10.1016\/j.jddst.2025.107635","volume":"115","author":"S Sezen","year":"2026","unstructured":"Sezen S, Ozakar RS, Bayram C, Burul F, \u00d6zkaraca M, Karaday\u0131 M, Deniz FE, Hac\u0131m\u00fcft\u00fco\u011flu A, G\u00fcll\u00fcce M (2026) A Plantago lanceolata L. extract-based cream enhances wound healing by modulating inflammatory mediators and growth factors in a full-thickness wound model: in vivo and in silico evidence. J Drug Deliv Sci Technol 115(Pt 1):107635. https:\/\/doi.org\/10.1016\/j.jddst.2025.107635","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"2241_CR74","doi-asserted-by":"publisher","first-page":"19478","DOI":"10.1038\/s41598-023-46576-0","volume":"13","author":"A Sl\u00e9zia","year":"2023","unstructured":"Sl\u00e9zia A, Heged\u00fcs P, Rusina E, Lengyel K, Solari N, Kaszas A, Bal\u00e1zsfi D, Botzanowski B, Acerbo E, Missey F, Williamson A, Hangya B (2023) Behavioral, neural and ultrastructural alterations in a graded-dose 6-OHDA mouse model of early-stage Parkinson\u2019s disease. Sci Rep 13(1):19478. https:\/\/doi.org\/10.1038\/s41598-023-46576-0","journal-title":"Sci Rep"},{"issue":"5","key":"2241_CR75","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1007\/s10787-024-01510-2","volume":"32","author":"D Soni","year":"2024","unstructured":"Soni D, Upadhayay S, Dhureja M, Arthur R, Kumar P (2024) Crosstalk between gut-brain axis: unveiling the mysteries of gut ROS in progression of Parkinson\u2019s disease. Inflammopharmacology 32(5):2921\u20132941. https:\/\/doi.org\/10.1007\/s10787-024-01510-2","journal-title":"Inflammopharmacology"},{"issue":"5","key":"2241_CR76","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/cells14050338","volume":"14","author":"A Spinaci","year":"2025","unstructured":"Spinaci A, Buccioni M, Dal Ben D, Francucci B, Klotz KN, Marucci G, Simola N, Morelli M, Pinna A, Volpini R, Lambertucci C (2025) A2A adenosine receptor antagonists and their efficacy in rat models of Parkinson\u2019s disease. Cells 14(5):338. https:\/\/doi.org\/10.3390\/cells14050338","journal-title":"Cells"},{"key":"2241_CR77","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3389\/fnins.2018.00693","volume":"12","author":"TB Stoker","year":"2018","unstructured":"Stoker TB, Torsney KM, Barker RA (2018) Emerging treatment approaches for Parkinson\u2019s disease. Front Neurosci 12:693. https:\/\/doi.org\/10.3389\/fnins.2018.00693","journal-title":"Front Neurosci"},{"issue":"5","key":"2241_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","volume":"20","author":"E Tolosa","year":"2021","unstructured":"Tolosa E, Garrido A, Scholz SW, Poewe W (2021) Challenges in the diagnosis of Parkinson\u2019s disease. Lancet Neurol 20(5):385\u2013397. https:\/\/doi.org\/10.1016\/S1474-4422(21)00030-2","journal-title":"Lancet Neurol"},{"key":"2241_CR79","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s00210-023-02568-5","volume":"396","author":"E Toraman","year":"2023","unstructured":"Toraman E, Bayram C, Sezen S, \u00d6zkaraca M, Hac\u0131m\u00fcft\u00fco\u011flu A, Budak H (2023) Parthenolide as a potential analgesic in the treatment of paclitaxel-induced neuropathic pain: the rat modeling. Naunyn Schmiedebergs Arch Pharmacol 396:3707\u20133721. https:\/\/doi.org\/10.1007\/s00210-023-02568-5","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"2241_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jphs.2018.08.008","volume":"138","author":"Y Wang","year":"2018","unstructured":"Wang Y, Yu X, Zhang P, Ma Y, Wang L, Xu H, Sui D (2018) Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson\u2019s disease. J Pharmacol Sci 138(1):31\u201337. https:\/\/doi.org\/10.1016\/j.jphs.2018.08.008","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"2241_CR81","doi-asserted-by":"publisher","first-page":"11738","DOI":"10.18632\/aging.202868","volume":"13","author":"WW Wang","year":"2021","unstructured":"Wang WW, Han R, He HJ, Li J, Chen SY, Gu Y, Xie C (2021) Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson\u2019s disease models. Aging 13(8):11738\u201311751. https:\/\/doi.org\/10.18632\/aging.202868","journal-title":"Aging"},{"key":"2241_CR82","unstructured":"World Health Organization (2023) Parkinson disease. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/parkinson-disease. Accessed 27 April 2023"},{"issue":"2","key":"2241_CR83","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2337\/dc22-1705","volume":"46","author":"CY Wu","year":"2023","unstructured":"Wu CY, Iskander C, Wang C, Xiong LY, Shah BR, Edwards JD, Kapral MK, Herrmann N, Lanct\u00f4t KL, Masellis M, Swartz RH, Cogo-Moreira H, MacIntosh BJ, Rabin JS, Black SE, Saskin R, Swardfager W (2023) Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study. Diabetes Care 46(2):297\u2013304. https:\/\/doi.org\/10.2337\/dc22-1705","journal-title":"Diabetes Care"},{"issue":"2","key":"2241_CR84","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.bbrc.2010.10.023","volume":"402","author":"M Yamada","year":"2010","unstructured":"Yamada M, Kida K, Amutuhaire W, Ichinose F, Kaneki M (2010) Gene disruption of caspase-3 prevents MPTP-induced Parkinson\u2019s disease in mice. BBRC 402(2):312\u2013318. https:\/\/doi.org\/10.1016\/j.bbrc.2010.10.023","journal-title":"BBRC"},{"issue":"8","key":"2241_CR85","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.clinthera.2013.06.017","volume":"35","author":"L Yang","year":"2013","unstructured":"Yang L, Li H, Li H, Bui A, Chang M, Liu X, Kasichayanula S, Griffen SC, Lacreta FP, Boulton DW (2013) Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Ther 35(8):1211\u20131222e2. https:\/\/doi.org\/10.1016\/j.clinthera.2013.06.017","journal-title":"Clin Ther"},{"issue":"4","key":"2241_CR86","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/jcp.26760","volume":"234","author":"H Yaribeygi","year":"2019","unstructured":"Yaribeygi H, Atkin SL, Butler AE, Sahebkar A (2019) Sodium-glucose cotransporter inhibitors and oxidative stress: an update. J Cell Physiol 234(4):3231\u20133237. https:\/\/doi.org\/10.1002\/jcp.26760","journal-title":"J Cell Physiol"},{"issue":"9","key":"2241_CR87","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.3390\/ijms25094643","volume":"25","author":"LX Yi","year":"2024","unstructured":"Yi LX, Tan EK, Zhou ZD (2024) Tyrosine hydroxylase inhibitors and dopamine receptor agonists combination therapy for Parkinson\u2019s disease. Int J Mol Sci 25(9):4643. https:\/\/doi.org\/10.3390\/ijms25094643","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2241_CR88","first-page":"14","volume":"3","author":"MA Y\u00f6r\u00fck","year":"2022","unstructured":"Y\u00f6r\u00fck MA, Okkay U, Budak Sava\u015f A, Bayram C, Sezen S, Ertu\u011frul MS, Hac\u0131m\u00fcft\u00fco\u011flu A (2022) Behavioral tests used in experimental animal models. Anatol J Biol 3(2):14\u201322","journal-title":"Anatol J Biol"},{"key":"2241_CR89","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00281-022-00947-3","volume":"44","author":"B Zhu","year":"2022","unstructured":"Zhu B, Yin D, Zhao H, Zhang L (2022) The immunology of Parkinson\u2019s disease. Semin Immunopathol 44:659\u2013672. https:\/\/doi.org\/10.1007\/s00281-022-00947-3","journal-title":"Semin Immunopathol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02241-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02241-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:25:45Z","timestamp":1781699145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02241-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2241"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02241-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article contains no studies on human subjects performed by any authors. All procedures performed in animal studies followed the ethical standards of the institution or practice at which the studies were conducted. Experiments were carried out at Atat\u00fcrk University Medical Experimental and Application Center-ATADEM with the approval received from Atat\u00fcrk University Animal Experiments Local Ethics Committee-HADYEK (Protocol number: 150, 24.06.2024).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}